

Krakow, 21st March 2025

REQUEST FOR PROPOSAL No. ABM-21032025A

In connection with the implementation by Ryvu Therapeutics S.A. of the project "The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent" no. 2022/ABM/06/00002/P/02 (hereinafter: "Project") co-financed from the state budget by the Medical Research Agency under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds no. ABM/2022/6, Ryvu Therapeutics S.A. invites proposals for the execution of the following defined description of the order.

I. ORDERING PARTY/SPONSOR

Ryvu Therapeutics S.A.
Sternbacha 2, 30-394 Krakow, Poland
EU VAT PL6792942955

II. DESCRIPTION OF THE ORDER

This order concerns **Investigator's Brochure (IB) annual update** in the phase II clinical study of a study drug in combination with a market drug in patients with AML.

Due to the need to protect business secrets, the description of the order (subject of the request) is made available to Bidders who undertake to maintain confidentiality. To vendors.clinical@ryvu.com must be sent the electronically signed CDA or information about CDA currently in force. The CDA template is attached as Appendix 03. The title of the message must contain the reference number of the RFP (ABM-21032025A).

III. CONDITIONS FOR PARTICIPATION IN THE PROCEEDINGS

Bidders meeting the following criteria are invited to submit a proposal:

- Bidders must publish final IB by 15-May-2025
- Bidders engaged in activities consistent with the description of the order and who have experience in the field performing activities corresponding with the description of the order for at least 3 years
- Bidders who are in a sound economic and financial condition to ensure the performance of the contract.
- Bidders who sufficient resources including any back-up personnel that might be needed to ensure the performance of the contract.
- Proposal validity period - minimum until 30th April 2025.

These conditions to be confirmed in Appendix 01 – Proposal form. The assessment of the conditions will be conducted using the system: meet/do not meet.

IV. PLACE, DATE PLACE, DATE AND PROCEDURE OF SUBMISSION OF QUOTES

- IV.1.** The proposal must be submitted by: **28th March 2025 at 23.59 CET.**
- IV.2.** The proposal must be sent via e-mail to the following address: vendors.clinical@ryvu.com. The message with the offer should refer to the RFP number indicated on the first page: **ABM-21032025A.**
- IV.3.** The proposal must be prepared in English.

- IV.4.** The proposal should be prepared in accordance with the form constituting Appendix 01 to this RFP and must include the following information: activities to be performed and the role involved, including time commitment and hourly rates.

The Bidders must provide the total price for the execution of the order consisted with the Description of the Order. The proposal must include prices given in EUR.

V. ADDITIONAL INFORMATION

- V.1.** The Ordering Party allows for the possibility of awarding to the Contractor supplementary orders, in an amount not exceeding 50% of the value of the contract specified in the agreement concluded with the contractor, while such orders are consistent with the subject of the basic contract.
- V.2.** The terms and conditions of the agreement may change during the course of the agreement (Ordering Party reserves the right to amend the agreement):
- in terms of the timelines and term of the agreement – following changes in the scope of the study and Project (extension of the duration of the Project, extension of appropriate stages of the Project, change of research plans);
 - in the event of force majeure as an event which is externally impossible to foresee and which could not have been prevented and whose consequences and effects could not have been prevented.
 - Ordering Party reserves the right to make changes to the final contract based on the requirements of the study protocol.
- V.3.** The Bidders may ask the Ordering Party to clarify the content of the RFP. If the request for clarification of the content of the RFP was received later than by the end of 26th March 2025, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: vendors.clinical@ryvu.com.
- V.4.** Due to the need to protect business secrets, in the event of questions requiring the disclosure of confidential data, the Ordering Party reserves the right to provide explanations after executing the Confidential Disclosure Agreement (CDA). It is allowed to use an electronic signature (including a qualified electronic signature) or a trusted signature (trusted profile).
- V.5.** The Ordering Party reserves the right to change the content of the RFP, including changes in the terms of the procedure. Bidders will be informed.
- V.6.** The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of offers for additional information, documents, calculations or explanations to the accuracy of the price quote or other requirements specified in the RFP. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the offer sent by the Bidder.
- V.7.** This RFP serves to estimate the market price of the contract. The Ordering Party reserves the right to enter into negotiations with Bidders who have submitted an offer and meet the conditions for participating in the proceedings. Arrangements regarding the date of negotiations will be carried out by e-mail. The modified offer may not contain conditions less favorable than the original proposal.
- V.8.** This RFP does not oblige the Ordering Party to conclude a contract.
- V.9.** For more information, please contact Anna Dziejdzicka or Agata Marszał-Kłosowska at the following email address: vendors.clinical@ryvu.com.

ATTACHMENTS:

Appendix 01 – Proposal Form;

Appendix 02 – Description of the order;

Appendix 03 – Mutual Confidentiality Agreement.